Literature DB >> 1975268

Myasthenia gravis and thymoma in multiple endocrine neoplasia (MEN-1) syndrome.

L J Vroegindeweij-Claessens, C C Tijssen, G J Creemers, J H Lockefeer, J L Teepen.   

Abstract

Entities:  

Mesh：

Year:  1990        PMID： 1975268      PMCID： PMC488149          DOI： 10.1136/jnnp.53.7.624

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  6 in total

1.  Hyperparathyroidism, chemodectoma, thymoma, and myasthenia gravis.

Authors:  F J Palmer; T M Sawyers
Journal:  Arch Intern Med       Date:  1978-09

2.  Mediastinal endocrine neoplasm in patients with multiple endocrine adenomatosis. A previously unrecognized association.

Authors:  J Rosai; E Higa; J Davie
Journal:  Cancer       Date:  1972-04       Impact factor: 6.860

3.  Carcinoid tumor of the thymus with multiple endocrine adenomatosis.

Authors:  D Floros; T Dosios; A Tsourdis; N Yiatromanolakis
Journal:  Pathol Res Pract       Date:  1982-12       Impact factor: 3.250

4.  Thymic carcinoid in familial multiple endocrine adenomatosis.

Authors:  J L Manes; H B Taylor
Journal:  Arch Pathol       Date:  1973-04

Review 5.  Multiple endocrine neoplasia syndromes.

Authors:  C J Lips; H F Vasen; C B Lamers
Journal:  Crit Rev Oncol Hematol       Date:  1984       Impact factor: 6.312

6.  Myasthenia gravis. A survey.

Authors:  H J Oosterhuis
Journal:  Clin Neurol Neurosurg       Date:  1981       Impact factor: 1.876
  6 in total
  2 in total

1.  Thymoma (World Health Organization type B3) with neuroendocrine differentiation in multiple endocrine neoplasia type 1.

Authors:  Masaki Tomita; Nobuhiko Ichiki; Takanori Ayabe; Hiroyuki Tanaka; Hiroaki Kataoka; Kunihide Nakamura
Journal:  J Surg Case Rep       Date:  2017-04-04

2.  p.L105Vfs mutation in a family with thymic neuroendocrine tumor combined with MEN1: a case report.

Authors:  Hongjuan Zheng; Shishi Zhou; Wanfen Tang; Qinghua Wang; Xia Zhang; Xiayun Jin; Ying Yuan; Jianfei Fu
Journal:  BMC Neurol       Date:  2020-03-04       Impact factor: 2.474
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.